Synergy Pharmaceuticals Stock Predictions

Buy SGYP

*Your capital is at risk

$0.0064

+0 (+0%)

At Close: Sep 17, 2019

Currently predicting for Mon, 8 Jun 2026

SGYP Prediction Chart

SGYP Predictions History

Latest community submissions for SGYP.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
JS Pro	Jan 12, 2018	$2.43 +1.67%	$2.39	X	98.33%	0
bbullish2 Merchant @bbullish2.7792	Jan 12, 2018	$2.44 +2.09%	$2.39	X	97.91%	0
JoeStockTrader	Jan 2, 2018	$2.24 -8.57%	$2.45	X	91.40%	0
lee.stevens.4118	Apr 24, 2017	$4.15 +0.97%	$4.11	X	99.00%	1
JS Pro	Mar 27, 2017	$4.65 -2.72%	$4.78	X	97.30%	0
Jack.Cesario.Migueis.3576 Amateur	Mar 27, 2017	$5.09 +6.49%	$4.78	X	93.50%	0
JS Pro	Mar 6, 2017	$5.82 +4.49%	$5.57	X	95.50%	0
Liam.Siegler.2602	Jan 31, 2017	$6.81 -3.68%	$7.07	X	96.30%	0
JS Pro	Dec 23, 2016	$4.84 -16.12%	$5.77	X	83.90%	0
Nick	Aug 29, 2016	$4.80 +1.48%	$4.73	X	98.50%	1

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for SGYP with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT SYNERGY PHARMACEUTICALS

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333,...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
RUN $12.83	4.09%	May 06
GLBE $31.61	1.65%	May 05
SAP $172.39	7.18%	May 05
FIZZ $34.11	7.04%	May 01
ADBE $243.57	3.23%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by